PTGS2 and hypertensive disorder: Previous studies have reported that the use of celecoxib is associated with a reduced risk in developing or losing control of hypertension, as well as with a reduced risk of acute cardiovascular events, than it is with selective COX-2 inhibitors, in particular, rofecoxib (31,34,35).